Author Identifier
Benhur Amanuel: https://orcid.org/0000-0002-2423-8334
Document Type
Journal Article
Publication Title
Pathology
Publisher
Elsevier
School
School of Medical and Health Sciences
Publication Unique Identifier
10.1016/j.pathol.2025.02.001
Funders
AstraZeneca Australia
Abstract
Molecular testing plays a critical role in guiding optimal treatment decisions for lung cancer patients across a variety of clinical settings. While guidelines for biomarker testing exist in other jurisdictions, to date no best practice guidelines have been developed for the Australian setting. To address this need, the Royal College of Pathologists of Australasia collaborated with the Thoracic Oncology Group of Australasia to identify state-based pathologists, oncologists and consumer representatives to develop consensus best practice recommendations. Sixteen recommendations were established encompassing appropriate biomarkers, lung cancer subtype, tumour stage, specimen types, assay selection and quality assurance protocols that can inform and standardise best practice in molecular testing of lung cancer. These multidisciplinary evidence-based recommendations are designed to standardise and enhance molecular testing practices for lung cancers and should help ensure laboratories provide high-quality molecular testing of lung cancer for all Australians, including those from regional or remote communities.
DOI
10.1016/j.pathol.2025.02.001
Creative Commons License
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 4.0 License.
Comments
Cooper, W. A., Amanuel, B., Cooper, C., Fox, S. B., Graftdyk, J. W., Jessup, P., ... & Pavlakis, N. (2025). Molecular testing of lung cancer in Australia: Consensus best practice recommendations from the Royal College of Pathologists of Australasia in collaboration with the Thoracic Oncology Group of Australasia. Pathology, 57(4), 425-436. https://doi.org/10.1016/j.pathol.2025.02.001